Broadly neutralizing antibodies for the treatment and prevention of HIV infection
Purpose of review Several anti-HIV-1 broadly neutralizing antibodies (bNAbs) with exceptional breadth and potency, and targeting different HIV-1 envelope epitopes have entered clinical trials. bNAbs are being evaluated for their potential as long-acting alternatives to antiretrovirals in HIV-1 prevention and therapy, and for potential role in strategies aiming at long-term viral remission. Here, we discuss recent findings from bNAb clinical studies. Recent findings bNAbs targeting distinct HIV-1 envelope epitopes have shown, in general, favorable safety profiles, and engineered bNAb variants have demonstrated improved pharmacokinetics. Single bNAb infusions transiently decreased viremia with subsequent selection of escape variants, while a combination of two bNAbs successfully maintained viral suppression in individuals harboring antibody-sensitive viruses after antiretroviral therapy (ART) was discontinued. Studies in animal models suggest that bNAbs can modulate immune responses and potentially interfere with the establishment or composition of the latent reservoir, and ongoing clinical studies aim to assess potential bNAb-mediated effects on HIV-1 persistence and host immune responses. Summary Early clinical studies support additional evaluation of bNAbs. Antibodies may offer advantages over standard ART for HIV-1 prevention and therapy, and as components of immunologic strategies to achieve sustained virologic control. The evaluation of engineered bNAbs with multi...
Publication date: Available online 16 January 2020Source: Biocybernetics and Biomedical EngineeringAuthor(s): Julian Andres Ramirez-Bautista, Jorge Adalberto Huerta-Ruelas, László T. Kóczy, Miklós F. Hatwágner, Silvia L. Chaparro-Cárdenas, Antonio Hernández-ZavalaAbstractLoad distribution analysis on foot surface allows knowing human mechanical behavior and aids the doctor in the detection of gait disorders like, the risk of foot ulcerations, leg discrepancy, and footprint alterations. Plantar pressure data combined with techniques that use integral reasoning produce easy un...
On this episode of ASHA Voices, we dive into the research behind hearing loss reversal. While investigating a genetic form of hearing loss affecting transduction, researcher Jeff Holt found he could successfully reverse hearing loss in mice. How did the researcher test the rodents’ hearing? By unexpectedly playing loud music and looking for a response in the subjects, nicknamed Beethoven mice. “A deaf mouse doesn’t jump at all, no matter how loud a sound you play. But after introducing our gene therapy into the ears of Beethoven mice, we find they jump again,” says Holt. Also on the show, sens...
Nationwide improvements in insurance coverage and access to care seen, even in nonexpansion states
This report describes that human immunodeficiency virus partner services for transgender women must address social and structural barriers unique to this population.
Doubling the dose of influenza vaccine for pregnant women with HIV moderately improves immunogenicity compared to a single flu shot, but response remains well below that of pregnant women without HIV, a clinical trial shows.Reuters Health Information
[Daily Maverick] You're far more likely to be offered an HIV test at a government health facility than at your GP or workplace clinic.
[The Herald] MANICALAND Province has made strides in the fight against HIV, amid indications the prevalence rate has declined compared to the national rate, a development attributed to awareness and access to treatment.
[FrontPageAfrica] Southeastern Liberia -About 73 representatives of local county authorities, Ministry of Health, County Health Officers; the private sector; faith-based organizations; traditional leaders; civil society groups; human rights groups; community-based organizations, key populations to TB/HIV, women-based groups, persons living with HIV; people who are most vulnerable to and affected by the diseases drawn from three of Liberia's 15 political subdivisions, Sinoe, Rivercess, Grand Gedeh have completed a two-day regional country dialogu
We described ART initiation characteristics and the probability of mortality, loss to follow-up (LTFU) and transfer out after 6 months on ART and assessed factors associated with mortality and LTFU. Results: A total of 1847 infants started ART at a median age of 60 days [interquartile range: 29–77] and CD4 percentage (%) of 27% (18%–38%). Across ART initiation calendar periods 2006–2009 to 2013–2017, ART initiation age decreased from 68 (53–81) to 45 days (7–71) (P